← Product Code [LHN](/productcode/LHN) · K260174 # PROBEAT-CR (K260174) _Hitachi High-Tech Corp. · LHN · Jun 11, 2026 · Radiology · SESE_ **Canonical URL:** https://fda.innolitics.com/device/K260174 ## Device Facts - **Applicant:** Hitachi High-Tech Corp. - **Product Code:** [LHN](/productcode/LHN.md) - **Decision Date:** Jun 11, 2026 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 892.5050 - **Device Class:** Class 2 - **Review Panel:** Radiology - **Attributes:** Therapeutic ## Indications for Use The PROBEAT-CR is a medical device designed to produce and deliver a proton beam for the treatment of patients with localized tumors and other conditions susceptible to treatment by radiation. ## Device Story Proton beam therapy system; produces/delivers therapeutic proton beams for localized tumor treatment. Components: accelerator (synchrotron/LINAC), beam transport, rotating gantry, scanning nozzle, patient positioning system (6-DOF couch), X-ray imaging, cone beam CT (CBCT), and real-time image gated proton therapy (RGPT) software. Operated by clinical staff in radiation oncology settings. System uses CBCT and positioning image analysis system (PIAS) to verify patient alignment before/during treatment. Output: controlled proton beam dose distribution directed to treatment site. Benefits: precise radiation delivery to tumors while sparing surrounding healthy tissue. Modifications from predicate include updated accelerator configuration (RFQ), expanded range shifter options, and integrated Worklist Manager (WLM) for external OIS connectivity. ## Clinical Evidence No clinical data. Evidence consists of bench testing, including beam performance testing (dose shape/distribution), imaging guidance function (CBCT), and OIS interface/WLM functionality. Electrical safety and electromagnetic compatibility testing performed per IEC 60601-1 and IEC 60601-1-2. ## Technological Characteristics Proton beam therapy system; 70-230 MeV variable energy. Components: Synchrotron/LINAC accelerator, rotating gantry (360 degrees), scanning nozzle, 6-DOF patient couch, CBCT imager with bowtie filter. Connectivity: Integrated Worklist Manager (WLM) and Interface Software for proton Therapy (IST) for OIS. Software includes Real-time image gated proton therapy (RGPT). Sterilization: N/A (fixed installation). Standards: IEC 60601-1, IEC 60601-1-2. ## Regulatory Identification A medical charged-particle radiation therapy system is a device that produces by acceleration high energy charged particles (e.g., electrons and protons) intended for use in radiation therapy. This generic type of device may include signal analysis and display equipment, patient and equipment supports, treatment planning computer programs, component parts, and accessories. ## Predicate Devices - Hitachi Ltd., Healthcare Radiation Oncology Systems, Kashiwa, PROBEAT-CR Proton Beam Therapy Device ([K201042](/device/K201042.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0} **FDA** **U.S. FOOD & DRUG** ADMINISTRATION June 11, 2026 Hitachi High-Tech, Corp. Kashiwanoha % John Smith Partner Hogan Lovells US LLP 555 Thirteenth St., NW Washington, District of Columbia 20004 Re: K260174 Trade/Device Name: PROBEAT-CR Regulation Number: 21 CFR 892.5050 Regulation Name: Medical Charged-Particle Radiation Therapy System Regulatory Class: Class II Product Code: LHN Dated: May 10, 2026 Received: May 11, 2026 Dear John Smith: We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. U.S. Food & Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 www.fda.gov {1} K260174 - John Smith Page 2 Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download). Your device is also subject to, among other requirements, the Quality Management System Regulation (QMSR) (21 CFR Part 820), which includes, but is not limited to, ISO 13485 clause 7.3 (Design controls), ISO 13485 clause 8.3 (Nonconforming product), ISO 13485 clause 8.5.2 (Corrective action), and ISO 13485 clause 8.5.3 (Preventative action). Please note that regardless of whether a change requires premarket review, the QMSR requires device manufacturers to review and approve changes to device design and production (ISO 13485 clause 7.3 and ISO 13485 clause 7.5) and document changes and approvals in the Medical Device File (ISO 13485 clause 4.2.3). Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the Quality Management System Regulation (QMSR) (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050. All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems. For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory- {2} K260174 - John Smith Page 3 assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely, Lora D. Weidner, Ph.D. Assistant Director Radiation Therapy Team DHT8C: Division of Radiological Imaging and Radiation Therapy Devices OHT8: Office of Radiological Health Office of Product Evaluation and Quality Center for Devices and Radiological Health Enclosure {3} # Indications for Use Please type in the marketing application/submission number, if it is known. This textbox will be left blank for original applications/submissions. K260174 ? Please provide the device trade name(s). ? PROBEAT-CR Please provide your Indications for Use below. ? The PROBEAT-CR is a medical device designed to produce and deliver a proton beam for the treatment of patients with localized tumors and other conditions susceptible to treatment by radiation. Please select the types of uses (select one or both, as applicable). ☑ Prescription Use (21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C) ? {4} K260174 Page 1 of 4 # **510(k) SUMMARY** **Hitachi High-Tech, Corp.'s PROBEAT-CR Proton Beam Therapy Device** **Submitter** Hitachi High-Tech, Corp. Kashiwanoha 226-44-141-1, Wakashiba, Kashiwa-shi, Chiba 277-0871, Japan Contact Person: Takanari Kuriyama Date Prepared: June 10, 2026 **Name of Device:** PROBEAT-CR **Common or Usual Name:** Proton Beam Therapy Device **Classification Name:** System, Radiation Therapy, Charged-Particle, Medical **Regulatory Class:** Class II **Product Code, Classification Regulation:** LHN, 21 C.F.R. § 892.5050 **Predicate Device** Hitachi Ltd., Healthcare Radiation Oncology Systems, Kashiwa, PROBEAT-CR Proton Beam Therapy Device (K201042) **Device Description** The PROBEAT-CR is a proton beam irradiation system, which provides a therapeutic proton beam for clinical treatment. It is designed to deliver a proton beam with the prescribed dose, dose distribution and directed to the prescribed patient treatment site. The PROBEAT-CR is a modification to the cleared PROBEAT-CR system (K201042). 14144-3156-0553 v3 {5} K260174 Page 2 of 4 ## Intended Use / Indications for Use The PROBEAT-CR is a medical device designed to produce and deliver a proton beam for the treatment of patients with localized tumors and other conditions susceptible to treatment by radiation. ## Summary of Technological Characteristics Consistent with the cleared PROBEAT-CR systems, the PROBEAT-CR comprises the following components and subsystems: - Beam production system - Accelerator system (LINAC, Synchrotron) - Beam transport system (Low/High Energy Beam Transport systems) - Beam delivery system - Gantry Room - Scanning Nozzle - Rotating Gantry - Patient Positioning System - X-ray Imaging System - Cone Beam CT - Positioning Image Analysis System - Real-time image gated proton therapy (RGPT) - Treatment Control and Safety System The PROBEAT-CR is a modification to the cleared PROBEAT-CR system. The system comprises the same components and subsystems as outlined above, with minor differences in design as summarized in the table below. | Comparison Item | Hitachi PROBEAT-CR | Hitachi PROBEAT-CR | | --- | --- | --- | | 510(k) Number | K260174 | K201042 | | Intended Use/ Indications for Use | The PROBEAT-CR is a medical device designed to produce and deliver a proton beam for the treatment of patients with localized tumors and other conditions susceptible to treatment by radiation. | The PROBEAT-CR is a medical device designed to produce and deliver a proton beam for the treatment of patients with localized tumors and other conditions susceptible to treatment by radiation. | | Accelerator | Synchrotron LINAC with Radio Frequency Quadrupole (RFQ). | Synchrotron LINAC with Drift tube and Radio Frequency Quadrupole (RFQ). | | Particle | Protons | Protons | | Variable energy | 70-230 MeV | 70-230 MeV | | Support for patient positioning | Gantry built-in type Cone Beam CT is used to verify patient positioning. | Gantry built-in type Cone Beam CT is used to verify patient positioning. | 14144-3156-0553 v3 {6} K260174 Page 3 of 4 | Comparison Item | Hitachi PROBEAT-CR | Hitachi PROBEAT-CR | | --- | --- | --- | | | A conventional x-ray system can be also equipped in the same treatment room. A computer assisted patient position system (PIAS) is available for use. | A conventional x-ray system can be also equipped in the same treatment room. A computer assisted patient position system (PIAS) is available for use | | Treatment rooms | Rotating gantry room. | Rotating gantry rooms and a fixed beam room. | | Gantry and rotating angle | Compact gantry 360 degrees | Compact gantry 360 degrees | | Patient Positioner | Rotating gantry room. a. Patient Couch Patient Positioning System with 6 degrees of freedom. b. Laser Alignment System | Rotating gantry room. a. Patient Couch Patient Positioning System with 6 degrees of freedom. b. Laser Alignment System | | Imager for patient positioning | CBCT + bowtie filter | CBCT | | Use of Image Gating System Software | Real Time Image Gating System software is incorporated into the system. | Real Time Image Gating System software is incorporated into the system. | | Beam adjustment | Range shifters 1 mm, 2 mm, 3mm, 4 mm, 5 mm, 40mm, Extendable Extended Range Shifter | Range shifters 3 mm, 40mm | | Treatment Management System Interface | Integrated Worklist Manager (WLM) and Interface Software for proton Therapy (IST) for external OIS connectivity | Interface Software for proton Therapy (IST) | ### Performance Data The company performed testing, as follows: - Beam performance testing to evaluate beam dose shape and beam dose - Imaging guidance function of CBCT - OIS interface and function of WLM test Further, electrical safety and electromagnetic compatibility testing was also performed in accordance with IEC 60601-1 and IEC 60601-1-2. In all instances, the PROBEAT-CR functioned as intended and met its specifications. Testing demonstrated substantial equivalence to the predicates. 14144-3156-0553 v3 {7} K260174 Page 4 of 4 ## Conclusions The PROBEAT-CR is as safe and effective as the predicate PROBEAT-CR System. PROBEAT-CR has the same intended uses and indications, similar technological characteristics, and principles of operation as its predicate device. The minor differences between the PROBEAT-CR that is the subject of this submission and the cleared PROBEAT-CR do not raise different questions of safety or effectiveness. Performance data demonstrate that the PROBEAT-CR is as safe and effective as the cleared PROBEAT-CR system. Thus, the PROBEAT-CR is substantially equivalent to its predicates. 14144-3156-0553 v3 --- **Source:** [https://fda.innolitics.com/device/K260174](https://fda.innolitics.com/device/K260174) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com